Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SAT1 | P21673 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177663 | 0.82 | ADRB2 (0.43) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL15510951 | 0.78 | TSHR (0.62) | TSHRCYP2C19KMT2AMEN1GLA | |
| SCHEMBL25565605 | 0.77 | ADRB2 (0.39) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL22802794 | 0.76 | TSHR (0.59) | TSHRCYP2C19KMT2AMEN1GLA | |
| SCHEMBL14235689 | 0.76 | TSHR (0.59) | TSHRCYP2C19KMT2AMEN1GLA | |
| SCHEMBL17150115 | 0.71 | DNM1 (0.42) | TSHRKMT2AMEN1ALDH1A1ADRB2 | |
| SCHEMBL15511439 | 0.71 | TSHR (0.59) | TSHRCYP2C19KMT2AMEN1GLA | |
| SCHEMBL36957 | 0.71 | — | — | |
| SCHEMBL22848917 | 0.70 | TSHR (0.56) | TSHRCYP2C19KMT2AMEN1GLA | |
| SCHEMBL8979943 | 0.70 | TSHR (0.56) | TSHRCYP2C19KMT2AMEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170178823-A1 | BORON CONTAINING PERYLENE MONOIMIDES, A PROCESS FOR THEIR PRODUCTION, THEIR USE AS BUILDING BLOCKS FOR THE PRODUCTION OF PERYLENE MONOIMIDE DERIVATIVES, MONOIMIDE DERIVATIVES AND THEIR USE IN DYE-SENSITIZED SOLAR CELLS | BASF SE (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170178823-A1 | BORON CONTAINING PERYLENE MONOIMIDES, A PROCESS FOR THEIR PRODUCTION, THEIR USE AS BUILDING BLOCKS FOR THE PRODUCTION OF PERYLENE MONOIMIDE DERIVATIVES, MONOIMIDE DERIVATIVES AND THEIR USE IN DYE-SENSITIZED SOLAR CELLS | BRSK1, BRSK2, BTD | TSHR 4809/4885CYP2C19 787/4885KMT2A 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.